At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer, Avelumab / Talazoparib in Patients With MSS Recurrent or Persistent Endometrial Cancer, and Avelumab / Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
In Brief
A Phase 2 clinical trial evaluating Avelumab, Talazoparib, and 1 other intervention for Metastatic Endometrial Cancer. Active but no longer recruiting, targeting 106 participants across 4 sites.
Detailed Summary
This research study is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial cancer.
Study Details
Timeline
Interventions
Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Premedication Antihistamine and Paracetamol will be administered prior to treatment
Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days
Axitinib will be taken twice per day by mouth Each Cycle lasts 28 days